TNF and glioblastoma: Of note, this product (called L19-TNF) has shown anti-tumor activity in a murine glioblastoma model [68] and is currently investigated in phase I/II trials in glioma patients at relatively high doses (10–13 μg/kg), as a single agent or combined with lomustine (clinicaltrials.gov; NCT03779230 and NCT04573192).